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Recent experimental studies have revealed that tumour-associated stromal macrophages as well as tumour cells express vascular
endothelial growth factor C (VEGF-C), which plays important roles in lymphangiogenesis, which is a critical factor in the progression
of many malignant tumours including non-small-cell lung cancer (NSCLC). However, no clinical study on VEGF-C expression in both
stromal macrophages and tumour cells has been reported, and we conducted the present study to address the issue in resected
NSCLC. A total of 206 patients with completely resected pathologic stage I–IIIA NSCLC were retrospectively reviewed. Expression
of VEGF-C in primary lung tumour was assessed immunohistochemically. Expression of VEGF-C in tumour cells was high in 125
patients (60.7%), and that in stromal macrophages was positive in 136 patients (71.2%). The status of VEGF-C in tumour cells or in
stromal macrophages was not correlated with nodal status or angiogenesis. The 5-year survival rate of high tumoral VEGF-C patients
(60.7%) was significantly lower than that of low tumoral VEGF-C patients (39.3%) (P¼0.046), and a multivariate analysis confirmed
that tumoral VEGF-C status was a significant and independent prognostic factor. Moreover, tumour showing high VEGF-A and VEGF-
C expression in tumour cells showed the poorest prognosis (5-year survival rate, 45.1%). The status of VEGF-C in stromal
macrophages was not correlated with the prognosis. In conclusion, tumoral VEGF-C status, not stromal VEGF-C status, was a
significant prognostic factor in resected NSCLC.
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Primary lung cancer is the leading cause of cancer deaths in most
industrialised countries, and non-small-cell lung cancer (NSCLC)
accounts for 75–80% of primary lung cancer. Tumour node
metastasis (TNM) factors are generally used in the evaluation of
tumour progression, and nodal involvement (N-factor) as well as
distant metastasis (M-factor) is the critical factor to determine the
prognosis of NSCLC (Mountain, 1997; Naruke et al, 1998; Tanaka
et al, 2000). In addition, some clinical studies demonstrated that
lymphatic invasion is also a prognostic factor in NSCLC (Macchiarini
et al, 1993; Brechot et al, 1996). Thus, lymphatic spread is a critical
factor to determine the progression and prognosis.
The vascular endothelial growth factor (VEGF) family is a group
of growth factors that regulate the growth of endothelial cells
(ECs). Among VEGF family members, it has been well known that
VEGF-A is the most potent angiogenic factor and plays important
roles in the progression of malignant tumours (Folkman, 1995).
Recently, VEGF-C has been identified as a new VEGF family
member (Paavonen et al, 1996; Cao et al, 1998; Yonekura et al,
1999), and it has been experimentally revealed that VEGF-C
mediates lymphangiogenesis (Makinen et al, 2001; Mandrisota
et al, 2001; Skobe et al, 2001). More recently, Padera et al (2002)
have revealed in an experimental mouse model that VEGF-C
expression correlates with the incidence of lymph node metastases.
These results strongly suggest that VEGF-C can be an important
diagnostic and therapeutic target for treating malignant tumours
(Pepper, 2001), but clinical significance of VEGF-C expression has
been established.
In NSCLC, only a few clinical studies on VEGF-C expression
have been reported (Niki et al, 2000; Ohta et al, 2000; Kajita et al,
2001; Arinaga et al, 2003), and the prognostic significance of
VEGF-C status remains controversial. In addition, in all these
studies, VEGF-C expression was analysed only in tumour cells,
whereas recent experimental and clinical studies revealed that
stromal cells, especially stromal macrophages, did express VEGF-C
and played important roles in peritumoral lymph angiogenesis
(Schoppmann et al, 2002; Krishnan et al, 2003). Thus, in the
present study, we assessed for the first time VEGF-C expression in
stromal macrophages as well as in tumour cells in correlation with
clinical outcomes in resected NSCLC.
PATIENTS AND METHODS
Patients and tissue preparation
A total of 206 patients with pathologic (p-) stage I–IIIA NSCLC
who underwent complete tumour resection without any preopera-
tive therapy at Kyoto University Hospital between January 1985
and December 1990 and whose histological specimens are available
for immunohistochemical staining (IHS) were retrospectively
reviewed (Table 1). Pathologic stage was re-evaluated and
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ldetermined with the present TNM classification as revised in 1997
(Mountain, 1997). Histological type and cell differentiation were
determined using the current classification by WHO as revised in
1999 (Travis et al, 1999). For analyses according to the
differentiation of cancer cells, well-differentiated squamous cell
carcinoma (Sq) and adenocarcinoma (Ad) were classified as well-
differentiated tumours and moderately differentiated Sq and Ad as
moderately differentiated tumours; large cell carcinoma (La) and
poorly differentiated Sq and Ad were classified as poorly
differentiated tumours, and the other histologic types were
excluded in the analyses. For all of these patients, records of
surgery, the in-patient medical records, chest X-ray films, whole-
body computed tomography (CT) films, and bone scanning films
were reviewed. Follow-up of postoperative clinical course was
conducted by outpatient medical records and by inquiries by
telephone or letter.
All of the primary tumour specimens were immediately fixed in
10% (vv
 1) formalin, and then embedded in paraffin. Serial 4-mm
sections were prepared from each sample, and served for
haematoxylin and eosin (HE) staining, the terminal deoxynucleo-
tidyl transferase (TdT)-mediated dUTP–biotin nick end-labelling
(TUNEL) staining, and IHS. Slides were reviewed independently by
two investigators (EO and KT) without a knowledge of any clinical
data. This study was approved by the Institutional Review Board of
Kyoto University.
Immunohistochemical staining
Expression of VEGF-C was evaluated with IHS using a streptavi-
din–biotinylated horseradish peroxidase detection system
(LSABþkit/HRP; DAKO, Kyoto, Japan). After retrieval of the
antigen with heating in a microwave oven for 15min, sections were
incubated overnight at 41C with an anti-VEGF-C goat polyclonal
antibody (N-19; Santa Cruz, San Diego, CA, USA) diluted at 1:50.
For the negative control, the primary antibody was omitted. As a
chromogen, diaminobenzidine-tetrahydrochloride (0.03%) con-
taining 0.1% hydrogen peroxide was used, and sections were
counterstained with haematoxylin. The expression of VEGF-C in
tumour cell was classified based on the staining intensity as
follows: score 0 if no staining was detected; score 1 if the staining
Table 1 Expression of VEGF-C in stromal macrophages and tumour cells in resected NSCLC
Expression of VEGF-C in
Stromal macrophages Tumour cells
Negative Positive P-value Low High P-value
All patients 55 (28.8) 136 (71.2) 81 (39.3) 125 (60.7)
Age (mean) 63.8 years 62.3 years 0.324 62.7 years 62.5 years 0.884
Lower (o64 years) 26 (28.3) 66 (71.7) 1.000 39 (38.6) 62 (61.4) 0.887
Higher (X64 years) 29 (29.3) 70 (70.7) 42 (40.0) 63 (60.0)
Gender
Male 44 (31.4) 96 (68.6) 0.124 59 (39.1) 92 (60.9) 1.000
Female 11 (21.6) 40 (78.4) 22 (40.0) 33 (60.0)
Performance status
0 48 (28.9) 118 (71.1) 71 (39.9) 107 (60.1)
1 7 (30.4) 16 (69.6) 0.657 10 (38.5) 16 (61.5) 0.515
2 0 (0.0) 2 (100) 0 (0.0) 2 (100)
Histologic type
Squamous cell 21 (30.4) 48 (69.6) 0.733
a 31 (40.8) 45 (59.2) 0.761
a
Adenocarcinoma 29 (27.6) 76 (72.4) 42 (37.8) 69 (62.2)
Large cell 2 (18.2) 9 (81.8) 5 (45.5) 6 (54.5)
Others 3 (50.0) 3 (50.0) 5 (62.5) 3 (37.5)
Tumour differentiation
Poor 11 (25.6) 32 (74.4) 19 (39.6) 29 (60.4)
Moderate 24 (30.0) 56 (70.0) 0.864 33 (39.8) 50 (60.2) 0.992
Well 17 (27.4) 45 (72.6) 26 (38.8) 41 (61.2)
Pathologic stage
I 35 (32.4) 73 (67.6) 48 (40.7) 70 (59.3)
II 6 (30.0) 14 (70.0) 0.363 12 (54.5) 10 (45.5) 0.151
IIIA 14 (22.2) 49 (77.8) 21 (31.8) 45 (68.2)
Pathologic (p-) T-factor
pT1 24 (35.8) 43 (64.2) 33 (45.8) 39 (54.2)
pT2 25 (25.5) 73 (74.5) 0.280 41 (38.7) 65 (61.3) 0.157
pT3 6 (23.1) 20 (76.9) 7 (25.0) 21 (75.0)
Pathologic (p-) N-factor
pN0 38 (30.9) 85 (69.1) 52 (38.5) 83 (61.5)
pN1 7 (31.8) 15 (68.2) 0.477 13 (54.2) 11 (45.8) 0.338
pN2 10 (21.7) 36 (78.3) 16 (34.0) 31 (66.0)
Each figure shows the number of patients, and the percentage is shown in parentheses.
aComparison between squamous cell carcinoma and adenocarcinoma.
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lintensity was weak; score 2 if the intensity was moderate; score 3 if
the intensity was high; VEGF-C status in tumour cells was finally
classified as low expression (score 0 or 1) or high expression (score
2 or 3). The expression of VEGF-C in stromal macrophages was
classified as negative or positive staining. For exact identification
of stromal macrophages, serial sections were used for IHS for
VEGF-C expression and IHS for CD68, which had been reported to
be a specific marker of macrophages; a mouse anti-CD68
monoclonal antibody (clone KP1; DAKO, Kyoto, Japan) diluted
at 1:2000 was used. Specificity of VEGF-C expression and
identification of stromal macrophages were confirmed by two
pathologists (KM and MT).
Expression of VEGF-A was also evaluated immunohistochemi-
cally as described previously (Tanaka et al, 2001). Briefly, an anti-
VEGF-A goat polyclonal antibody (A-20; Santa Cruz) diluted at
1:50 was used as the primary antibody, and status of VEGF-A
expression was classified based on the staining intensity and the
percentage of positive-staining tumour cells as low expression or
high expression (Tanaka et al, 2001).
Intratumoral microvessel density (IMVD), a measurement of
tumour angiogenesis, was evaluated immunohistochemically using
a mouse monoclonal antibody (QBEnd10, diluted at 1:50; DAKO)
against CD34, a pan-endothelial marker and a mouse monoclonal
antibody (SN6h, diluted at 1:100; DAKO) against CD105, a specific
marker of activated ECs, as described previously (Tanaka et al,
2001). The 10 most vascular areas within a section were selected
for evaluation of angiogenesis, and vessels labelled with the anti-
CD34 antibody or the anti-CD105 antibody were counted under
light microscopy with a 200-fold magnification. The average
counts were recorded as the CD34-IMVD or the CD105-IMVD for
each case.
Proliferative activity of tumour cells and p53 status were also
evaluated with IHS as described previously (Tanaka et al, 1999); an
anti-proliferative cell nuclear antigen (PCNA) monoclonal anti-
body PC-10 (mouse IgG2a, kappa, 400mmgml
 1; DAKO) diluted at
1:50 and an anti-p53 monoclonal antibody DO-7 (mouse IgG2b,
kappa, 250mgml
 1; DAKO) diluted at 1:50 were used as primary
antibodies, respectively. A total of 1000 tumour cells were counted,
and the percentages of positive cells were determined. Proliferative
index (PI) was defined as the percentage of PCNA-positive cells
(%); when the percentage of positive-staining cells exceeded 5%,
the slide was judged to exhibit aberrant expression of p53.
TUNEL staining
Detection of apoptotic cells was performed with the TUNEL
method as described previously (Tanaka et al, 1999). The TUNEL
staining was performed using the In Situ Death Detection Kit, POD
(Boehringer Manheim, Manheim, Germany) following the manu-
facturer’s protocol. The specificity of the TUNEL staining of
apoptotic cells was confirmed by making the negative and the
positive control slides at every staining. As negative control slides,
sections incubated with the TUNEL reaction mixture without TdT
were used. As positive control slides, sections treated with
0.7mgml
 1 DNase I (Stratagene, La Jolla, CA, USA) for 10min
at 251C before the TUNEL reaction were used. Apoptotic cells were
determined with careful observation of TUNEL-staining sections
and serial HE-staining sections, and TUNEL-staining cells, if they
represented the histological features of necrosis in HE-staining
sections, were not considered to be apoptotic cells. In each case, a
total of 10000 tumour cells, consisting of 1000 tumour cells each in
10 different fields, were evaluated at high magnification ( 400).
Statistical methods
Counts were compared by the w2 test. Continuous data were
compared using Student’s t-test if the sample distribution was
normal, or using Mann–Whitney U-test if the sample distribution
was asymmetrical. The postoperative survival rate was analysed by
the Kaplan–Meier method, and the differences in survival rates
were assessed by the log-rank test. Multivariate analysis of
prognostic factors was performed using Cox’s regression model.
Differences were considered significant when P was less than 0.05.
All statistical manipulations were performed using the SPSS for
Windows software system (SPSS Inc., Chicago, IL, USA).
RESULTS
Expression of VEGF-C in NSCLC
Expression of VEGF-C was seen in the cytoplasm of tumour cells
(Figure 1A), and high VEGF-C expression in tumour cells was seen
in 125 patients (60.7%) (Table 1). The status of VEGF-C in tumour
cells was not correlated with any patients’ characteristics including
nodal metastasis (Table 1).
The expression of VEGF-C was also seen in stromal macro-
phages (Figure 1B), and the expression was positive in 136 patients
(71.2%) (Table 1). No significant correlation between any patients’
characteristic and VEGF-C status in stromal macrophages was
documented (Table 1). A strongly positive correlation between
tumoral VEGF-C status and stromal VEGF-C status was docu-
mented (Po0.001) (Table 2).
The status of VEGF-C and other biomarkers
A significantly positive correlation between VEGF-C status in
tumour cells and VEGF-A status in tumour cells was documented
Figure 1 Expression of VEGF-C in NSCLC. Vascular endothelial growth factor C was observed in (A) tumour cells and (B) stromal macrophages.
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l(P¼0.026). Tumours showing aberrant expression of p53 seemed
to have higher incidence of high VEGF-C expression in tumour
cells, but the difference did not reach a statistical significance
(P¼0.062) (Table 2). No significant correlation between VEGF-C
status in angiogenesis, incidence of apoptosis, or proliferative
activity was seen (Table 2).
The mean PI for tumour showing positive VEGF-C expression
in stromal macrophages was significantly higher than that
for tumour showing no VEGF-C expression in stromal
macrophages. The status of VEGF-C in stromal macrophages
was not correlated with any other biomarker including IMVD
(Table 2).
Postoperative survival
The 5-year survival rate of high tumoral VEGF-C patients (67.9%)
was significantly lower than that of low tumoral VEGF-C patients
(53.5%) (P¼0.046; Table 3 and Figure 2). There was no difference
in the survival according to the VEGF-C status in stromal
macrophages (Table 3). A multivariate analysis confirmed that
high VEGF-C expression in tumour cells was a significant and
independent prognostic factor in resected NSCLC (Table 4).
When combined with VEGF-A status in tumour cells, the
prognostic impact of VEGF-C status in tumour cells was enhanced
(Figure 3). Tumour showing high VEGF-A and VEGF-C expression
Table 2 Biomarkers according to expression of VEGF-C in stromal fibroblasts and tumour cells in resected NSCLC
Expression of VEGF-C in
Stromal macrophages Tumour cells
Negative Positive P-value Low High P-value
VEGF-A expression in tumour cells
Low 35 (29.2) 85 (70.8) 1.000 59 (45.4) 71 (54.6) 0.026
High 20 (28.2) 51 (71.8) 22 (28.9) 54 (71.1)
VEGF-C expression in stromal macrophages
Low 36 (65.5) 19 (34.5) o0.001
High 36 (26.5) 100 (73.5)
VEGF-C expression in tumour cells
Negative 36 (50.0) 36 (50.0) o0.001
Positive 19 (16.0) 100 (84.0)
Intratumoral microvessel density (IMVD)
CD34-IMVD (mean) 191.1 183.3 0.623 175.3 189.9 0.306
CD105-IMVD (mean) 41.4 45.1 0.643 38.4 47.7 0.190
p53 aberrant expression
Negative 34 (31.2) 75 (68.8) 0.424 53 (44.9) 65 (55.1) 0.062
Positive 21 (25.6) 61 (74.4) 28 (31.8) 60 (68.2)
Apoptotic index (mean) 14.5 19.3 0.130 17.9 17.8 0.977
Proliferative index (mean) 36.6 48.3 0.008 43.2 47.6 0.281
Each figure shows the number of patients, and the percentage is shown in parentheses.
Table 3 Postoperative survival according to expression of VEGF-C in
NSCLC
Expression of VEGF-C in
Stromal macrophages Tumour cells
Negative
(%)
Positive
(%) P-value
Low
(%)
High
(%) P-value
All patients 57.3 60.3 0.921 67.9 53.5 0.046
Stratified with pathologic (p-) stage
p-Stage I 61.1 74.3 0.246 76.0 65.5 0.231
p-Stage II 44.4 69.2 0.329 66.7 44.4 0.559
p-Stage IIIA 53.9 33.2 0.117 48.8 33.5 0.176
Stratified with histologic type
Squamous cell 49.9 63.4 0.656 70.7 48.3 0.056
Adenocarcinoma 58.5 56.1 0.613 64.2 53.7 0.291
Each figure shows the 5-year survival rate of the each patient group.
Figure 2 Postoperative survival of completely resected p-stage I–IIIA
NSCLC. Comparison according to the status of VEGF-C expression in
tumour cells: patients who had high staining for VEGF-C showed
significantly less favourable survival rates compared with patients who
had low staining for VEGF-C (P¼0.046).
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lin tumour cells showed the poorest prognosis (5-year survival rate,
45.1%).
DISCUSSION
We reported for the first time VEGF-C expression in stromal
macrophages as well as in tumour cells in correlation with clinical
outcomes in resected NSCLC. In previous clinical studies, it has
been reported that VEGF-C status in tumour cells was significantly
correlated with nodal metastasis and/or lymphatic vessel invasion
in a variety of malignant tumours such as head and neck
carcinoma (Oc et al, 2001), thyroid carcinoma (Bunone et al,
1999; Fellmer et al, 1999), oesophageal carcinoma (Kitadai
et al, 2001; Noguchi et al, 2002), breast carcinoma (Kinoshita
et al, 2001), gastric carcinoma (Yonemura et al, 1999, 2001;
Kawashima et al, 2001), uterine carcinoma (Hashimoto et al, 2001;
Hirai et al, 2001; Schoppmann et al, 2002), prostate carcinoma
(Tsurusaki et al, 1999), and NSCLC (Niki et al, 2000; Ohta et al,
2000; Kajita et al, 2001; Arinaga et al, 2003). However, only one
clinical study on VEGF-C expression in stromal macrophages has
been reported, which showed that tumour-associated macrophages
express VEGF-C and play important roles in peritumoral
lymphangiogenesis in cervical cancer (Schoppmann et al, 2002).
We also demonstrated in the present study that stromal
macrophages did express VEGF-C in NSCLC. We failed to
demonstrate any correlation between VEGF-C status in tumour
cells or stromal cells and angiogenesis or nodal metastasis. To
assess more accurately a correlation between VEGF-C status and
nodal status, quantitative analysis of VEGF-C expression such as
real-time reverse transcriptase–polymerase chain reaction for
large-scale patient population should be conducted prospectively
in future studies.
Some clinical studies revealed that VEGF-C status in tumour
cells was a significant prognostic predictor in gastric carcinoma
(Yonemura et al, 1999; Ichikura et al, 2001) and cervical carcinoma
(Hirai et al, 2001), and the clinical impact remains unclear. In
NSCLC, only a few studies have assessed the prognostic
significance (Niki et al, 2000; Ohta et al, 2000; Kajita et al, 2001).
Tumoral VEGF-C status was a significant prognostic factor in a
univariate analysis, but a multivariate analysis failed to show a
statistical significance in two studies (Niki et al, 2000; Kajita et al,
2001); a univariate analysis failed to show that tumoral VEGF-C
expression was a significant prognostic factor in one study (Ohta
et al, 2000). The present study showed that high VEGF-C
expression in tumour cells was a significant and independent
factor to predict a poor prognosis, and that tumour with high
VEGF-A and VEGF-C expression in tumour cells showed the
poorest prognosis. Unfortunately, we failed to show any clinical
impact of VEGF-C status in stromal macrophages. To further
assess clinical impact of VEGF-C status in tumour cells and
stromal macrophages, expression status of the receptors such as
VEGFR-3 should also be examined.
In conclusion, VEGF-C is expressed by both tumour cells and
stromal cells in NSCLC, and VEGF-C status in tumour cells was
significantly correlated with the prognosis. These findings suggest
that VEGF-C may be an important target for diagnosis and/or
therapy of NSCLC. Further investigations are necessary to clarify
and understand the role of VEGF-C in patients with NSCLC.
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